The active ingredient found in popular medications for Type 2 diabetes and weight loss, including Ozempic and Wegovy, may reduce the risk of Alzheimer's disease, a new study published Thursday finds.

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also stave off dementia?

Weight loss drug Ozempic may also reduce the risk of dementia, suggests a new study. American researchers found that semaglutide - the active ingredient in Ozempic and another weight loss ...

Researchers at Case Western Reserve University have discovered that the popular diabetes and weight-loss drug Ozempic may lower a person’s risk of developing dementia.. The active ingredient in ...

The popular diabetes and weight-loss drug semaglutide may lower the risk of dementia when taken by Type 2 diabetes patients, new research from the Case Western Reserve School of Medicine suggests.

FAT jabs are better than widely prescribed metformin when it comes to curbing dementia risk in people with type 2 diabetes, ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Researchers followed 60,000 adults aged 40 and older—who took various types of antidiabetic medication—for seven years ...

A recent study revealed that weight loss drugs, GLP-1s, including Ozempic and Zepbound, may help in treating several chronic ...

A new scientific study has found that weight loss jabs such as Mounjaro and Ozempic can help protect against serious health ...

First, a drug like Ozempic mimics the natural GLP-1 hormone in your gut, which slows down digestion in the stomach and ...